Melatonin in Psychiatric Disorders
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 June 2019) | Viewed by 197
Special Issue Editor
Special Issue Information
Dear Colleagues,
Psychiatric disorders constitute a growing health burden worldwide. Melatonin has attracted particular interest due to the potential role as an aetiological factor in some disorders (e.g., bipolar disorder due to alteration in circadian rhythms). Melatonin agonists, such as agomelatine, have been approved for the treatment of major depression, while others may be of utility in the treatment of sleep disturbance associated with psychiatric disorders. Alteration of the sensitivity of melatonin to light and the daily secretion of the hormone have been proposed as biomarkers in some disorders. Melatonin itself has been proposed as a treatment for seasonal affective disorders as well as the metabolic syndrome associated with the use of atypical antipsychotic medications. The aetiological significance of melatonin secretion and rhythm alterations remains debatable, while the therapeutic effects, at least of the agonists, have a better evidence base. This Special Issue aims to identify and review data related to melatonin secretion, rhythms and the use of agonists in psychiatric disorders.
Prof. Dr. Trevor Norman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Melatonin
- Melatonin agonists
- Depression
- Bipolar disorder
- Antioxidant
- Anxiety disorders
- Treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
